JPMorgan Maintains an “Overweight rating” on Bruker Corporation (BRKR)

Bruker Corporation (NASDAQ:BRKR) is one of the 10 Best Brain-Computer Interface Stocks to Buy.

On June 8, JPMorgan analyst Casey Woodring raised the price target on Bruker Corporation (NASDAQ:BRKR) to $65 from $45. The firm maintained an "Overweight rating" on the share. It updated the company model.

Days earlier, on June 4, Bruker Corporation (NASDAQ:BRKR) reported its growing microbiology and infection diagnostics portfolio at ASM Microbe 2026. The firm detailed advances across microbial identification, sepsis diagnostics, molecular testing, and next-generation sequencing workflows.

The company said improvements to its MALDI Biotyper CA System include FDA-approved updates. It allows spotting of 549 clinically validated microbial species, along with software and workflow upgrades mapped out to improve speed and confidence in clinical labs.

Bruker also introduced new research-use tools. It includes libraries covering 5,325 species and more classifiers planned to strengthen outbreak investigation and surveillance.

The firm added that a rapid antimicrobial susceptibility testing workflow under development could make faster, actionable diagnostics to help earlier clinical decisio

Fuente original: Yahoo Finance (https://finance.yahoo.com/markets/stocks/articles/jpmorgan-maintains-overweight-rating-bruker-153154965.html)